SCHEMBL6442714

SCHEMBL6442714

CCOc1ncc(N)cc1C(=O)Nc1c(C(N)=O)nn(C)c1CC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.52
TERT O14746 2/20 0.36
ALDH1A1 P00352 3/20 0.32
NPC1 O15118 1/20 0.32
TSHR P16473 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
AURKA O14965 1/20 0.31
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31
TTK P33981 1/20 0.31
PLK1 P53350 1/20 0.31
CCNA1 P78396 1/20 0.31
NR3C1 P04150 1/20 0.31
GCK P35557 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6777123 0.92 PDE5A (0.47) PDE5ATERTALDH1A1NPC1TSHR
SCHEMBL3578605 0.88 PDE5A (0.49) PDE5ATERTALDH1A1TTKNR3C1
SCHEMBL6450443 0.85 PDE5A (0.49) PDE5ATERTALDH1A1L3MBTL1AURKA
SCHEMBL6197426 0.80 PDE5A (0.81) PDE5AALDH1A1KDM4EKMT2A
SCHEMBL6776964 0.78 PDE5A (0.44) PDE5ATERTALDH1A1AURKACCNA2
SCHEMBL6444767 0.76 PDE5A (0.40) PDE5AALDH1A1NPC1TSHRL3MBTL1
SCHEMBL3579254 0.74 PDE5A (0.46) PDE5ATERTALDH1A1NPC1KDM4E
SCHEMBL6446169 0.74 PDE5A (0.67) PDE5AALDH1A1TSHRCDK2KDM4E
SCHEMBL6446798 0.74 PDE5A (0.39) PDE5AALDH1A1NR3C1MEN1KMT2A
SCHEMBL6444664 0.73 PDE5A (0.74) PDE5AALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1371647-B1 Pyridine-3-carboxylic acid derivatives and their use as intermediates PFIZER (US) 2005-07-13 EP disclosed
EP-1371647-A2 Pyridine-3-carboxylic acid derivatives and their use as intermediates PFIZER INC. (US) 2003-12-17 EP disclosed
EP-1073658-B1 PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION PFIZER (US) 2003-08-13 EP disclosed
US-6458951-B2 FOR TREATMENT OF MALE ERECTILE DYSFUNCTION, FEMALE SEXUAL DYSFUNCTION PFIZER INC 2002-10-01 US disclosed
US-20010039271-A1 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction BUNNAGE MARK EDWARD (GB) 2001-11-08 US disclosed
US-6251904-B1 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction PFIZER INC. 2001-06-26 US disclosed
EP-1073658-A1 PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION PFIZER INC. (US) 2001-02-07 EP disclosed
WO-1999054333-A1 PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION PFIZER INC. (US) 1999-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039271-A1 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction PDE5A, PDE3A, PDE3B PDE5A 1/4885TERT 4439/4885ALDH1A1 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.